Please assess the completion status of the following clinical trial:

Trial Title: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written Informed Consent provided by patient~2. MM, with the following conditions:~(CLOSED) \*For patients in the Vanguard cohort\*~1. Treatment naïve disease with BM clinically indicated~\*For patients in the RRMM cohort\*~1. Relapsed/refractory disease with BM samples clinically indicated~2. Within 4-weeks prior to initiation of 2nd-line or later therapy~3. Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)~Exclusion Criteria:~1. Unable or unwilling to provide informed consent~2. Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable)~3. Patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study~4. Prior exposure to CAR-T therapy~5. Prior allogeneic stem cell transplant~6. Has received any systemic chemotherapy or RT, including palliative, within 7 days prior to BM biopsy~7. Has received any Ab therapy within 4 weeks prior to BM biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vanguard (Type: None): (CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
- Relapsed/Refractory MM (Type: None): BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.

Based on this trial design, predict the completion outcome and termination type (if applicable).